While the studies presented here suggest improved responsiveness of BRCA1/2-associated GCs to platinum-based intervention, other DNA damaging agents such as PARP inhibitors (PARPi) may also prove useful as PARPi have shown selective killing of BRCA1/2 mutant tumor cells [68,69]. This evidence concerns the gene BRCA1 and neoplasm.